🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Humana tops estimates on strength in Medicare and primary care

Published 10/30/2024, 06:50 AM
Updated 10/30/2024, 11:47 AM
© Reuters. FILE PHOTO: A screen displays the logo and trading information for Humana on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 6, 2023.  REUTERS/Brendan McDermid/File Photo
HUM
-

By Sriparna Roy and Amina Niasse

(Reuters) -Humana beat Wall Street estimates for third-quarter profit on Wednesday as it added more members than expected in its government-backed Medicare Advantage insurance business for older adults, and saw strength in its primary care segment CenterWell.

The health insurer, a top provider of Medicare Advantage plans, said it expects "at least" $16 per share in adjusted profit for the full year, compared with its previous forecast of "approximately" $16 per share.

Shares of the Louisville, Kentucky-based company rose more than 4% in morning trade.

For 2025, Humana (NYSE:HUM) said it expects adjusted profit to be at least in line with final 2024 results. Analysts expect a 2025 profit of $19.77 per share, according to data compiled by LSEG.

"We want to be appropriately prudent and make sure that we're doing the right things to establish targets, hit those targets, build credibility over time," Jim Rechtin, CEO of Humana said in a conference call. "We are trying to establish the best way to navigate through the next 24 months."

Insurers providing Medicare Advantage plans have faced challenges recently due to rising healthcare expenses among older adults. These challenges were compounded by recent government payment rates, making it difficult for insurers to cover the higher medical costs without impacting profits.

Concerns about 2024 have been alleviated, but expectations for 2025 suggest a flat year with minimal growth, which is "a much lower bar than expected," said Baird analyst Michael Ha.

PERFORMANCE RATINGS

Humana shares, among the sector's most hard hit, have fallen nearly 44% so far this year, after the company withdrew its 2025 forecast previously, citing disappointing government Medicare reimbursement rates.

Humana launched a suit in October against the U.S. Department of Health and Human Services over the Medicare agency's calculation of its performance ratings.

A downgrade in the quality rating for a widely used Medicare insurance plan, which accounts for nearly half of its Medicare Advantage (MA) memberships, could potentially weigh on the insurer's revenue and bonus payments in 2026.

For 2027, the company expects to return its Medicare Advantage margins to at least 3%, but that target is at risk of erosion following drops in Humana's quality rating, Rechtin said.

For the full year, Humana anticipates individual net membership growth in its MA business of about 265,000, up from its previous estimate of about 225,000.

Humana's appeal of its quality rating will not have a significant impact on the company's future investments, Rechtin said.

The company also warned of higher than expected inpatient admissions - hospitalizations that require an overnight stay.

Humana Chief Financial Officer Susan Diamond said the company saw an initial uptick in inpatient claim appeals following the implementation in 2023 of a CMS rule that defines an inpatient facility as one where patients stay two nights.

Inpatient claim appeals have leveled off since and remain in line with first-quarter figures, Diamond said.

Humana reported a third-quarter medical cost ratio - the percentage of premiums spent on medical care - of 89.9%, in line with analyst expectations.

© Reuters. FILE PHOTO: A screen displays the logo and trading information for Humana on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 6, 2023.  REUTERS/Brendan McDermid/File Photo

Revenue at its CenterWell segment rose 8% to $5.04 billion for the quarter.

Humana also posted an adjusted profit of $4.16 per share, beating estimates of $3.40.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.